HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HEPA

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/20	05 : 30	GlobeNewswire Inc.	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/16	23 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/16	22 : 00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/15	05 : 38	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/01/04	07 : 15	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present at NASH-TAG 2024	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/01/04	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/12/07	22 : 00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/29	06 : 15	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/14	06 : 05	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/10	22 : 50	GlobeNewswire Inc.	Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/09	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/10/25	21 : 30	GlobeNewswire Inc.	Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/29	21 : 00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/22	05 : 05	GlobeNewswire Inc.	Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/21	21 : 00	GlobeNewswire Inc.	New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/19	22 : 00	GlobeNewswire Inc.	Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/18	21 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/14	21 : 45	GlobeNewswire Inc.	Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/07	05 : 40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/07	05 : 30	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Management Changes	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/25	05 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/22	05 : 41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/22	05 : 39	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/06/16	05 : 45	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/06/15	21 : 22	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/25	05 : 45	GlobeNewswire Inc.	Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/22	20 : 00	GlobeNewswire Inc.	Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/20	05 : 05	GlobeNewswire Inc.	Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/13	05 : 19	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/11	00 : 15	GlobeNewswire Inc.	Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split	NASDAQ:HEPA	Hepion Pharmaceuticals Inc